[go: up one dir, main page]

DK1667693T3 - Præparater og fremgangsmåder til anvendelse af lamellare bodies til terapeutiske formål - Google Patents

Præparater og fremgangsmåder til anvendelse af lamellare bodies til terapeutiske formål Download PDF

Info

Publication number
DK1667693T3
DK1667693T3 DK04768271.1T DK04768271T DK1667693T3 DK 1667693 T3 DK1667693 T3 DK 1667693T3 DK 04768271 T DK04768271 T DK 04768271T DK 1667693 T3 DK1667693 T3 DK 1667693T3
Authority
DK
Denmark
Prior art keywords
preparations
methods
therapeutic purposes
lamellar bodies
lamellar
Prior art date
Application number
DK04768271.1T
Other languages
English (en)
Inventor
James Lamellar Therapeutics Limited Dobbie
Original Assignee
Lamellar Biomedical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lamellar Biomedical Ltd filed Critical Lamellar Biomedical Ltd
Priority claimed from PCT/GB2004/003722 external-priority patent/WO2005030226A1/en
Application granted granted Critical
Publication of DK1667693T3 publication Critical patent/DK1667693T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK04768271.1T 2003-09-25 2004-08-31 Præparater og fremgangsmåder til anvendelse af lamellare bodies til terapeutiske formål DK1667693T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0322448.2A GB0322448D0 (en) 2003-09-25 2003-09-25 Using lamellar bodies to modify linear biological macro molecules
US10/827,172 US20050070877A1 (en) 2003-09-25 2004-04-19 Compositions and methods of using lamellar bodies for modifying linear biological macromolecules
PCT/GB2004/003722 WO2005030226A1 (en) 2003-09-25 2004-08-31 Compositions and methods of using lamellar bodies for therapeutic purposes

Publications (1)

Publication Number Publication Date
DK1667693T3 true DK1667693T3 (da) 2015-08-31

Family

ID=29286803

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04768271.1T DK1667693T3 (da) 2003-09-25 2004-08-31 Præparater og fremgangsmåder til anvendelse af lamellare bodies til terapeutiske formål

Country Status (9)

Country Link
US (4) US20050070877A1 (da)
CY (1) CY1116815T1 (da)
DK (1) DK1667693T3 (da)
ES (1) ES2543979T3 (da)
GB (1) GB0322448D0 (da)
HU (1) HUE025129T2 (da)
NZ (1) NZ546388A (da)
PT (1) PT1667693E (da)
SI (1) SI1667693T1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
GB0322448D0 (en) * 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
US9597458B2 (en) 2009-10-29 2017-03-21 W. L. Gore & Associates, Inc. Fluoropolymer barrier materials for containers
US10471212B2 (en) * 2009-10-29 2019-11-12 W. L. Gore & Associates, Inc. Silicone free drug delivery devices
US11612697B2 (en) 2010-10-29 2023-03-28 W. L. Gore & Associates, Inc. Non-fluoropolymer tie layer and fluoropolymer barrier layer
AU2015204395B2 (en) * 2011-05-27 2017-02-23 W. L. Gore & Associates, Inc. Fluoropolymer barrier materials for containers
JP5701371B2 (ja) * 2012-12-28 2015-04-15 花王株式会社 スフィンゴミエリン含有サプリメント
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
GB201511058D0 (en) * 2015-06-23 2015-08-05 Lamellar Biomedical Ltd Compositions and methods for using lamellar bodies for therapeutic purposes
EP3313413B1 (en) 2015-09-28 2024-12-04 Azura Ophthalmics Ltd Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
EP3442519A4 (en) 2016-04-14 2019-12-04 Azura Opthalmics Ltd. SELDISULFID COMPOSITIONS FOR USE IN THE TREATMENT OF THE MEIBOM DRESSING DYSFUNCTION
JP2023510499A (ja) 2020-01-10 2023-03-14 アズーラ オフサルミックス エルティーディー． 組成物および過敏症のための指示

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925375A (en) * 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
US5403592A (en) 1987-08-25 1995-04-04 Macnaught Pty Limited Lubricant composition for rheumatism
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
FR2645878B1 (fr) * 1989-04-17 1994-02-25 Institut Nal Sante Recherc Medic Sequences nucleotidiques d'actinomycetales, applications a la synthese ou a la detection d'acides nucleiques, produits d'expression de ces sequences et application en tant que compositions immunogenes
JPH02295933A (ja) 1989-05-10 1990-12-06 Wakamoto Pharmaceut Co Ltd 封入純度の高いプラスミノーゲン活性化因子封入リポソームの製造法
WO1991012026A1 (en) 1990-02-14 1991-08-22 Macnaught Pty Limited Means of reducing surgical adhesions
FR2658418B1 (fr) * 1990-02-20 1994-09-02 Synthelabo Compositions pharmaceutiques a base de phospholipides.
EP0544862B1 (en) 1991-05-29 1998-03-18 Baxter International Inc. Methods and compositions for the prevention, diagnosis, and treatment of inflammatory serosal diseases and related conditions
WO1995008986A1 (en) 1993-09-27 1995-04-06 Smithkline Beecham Corporation Camptothecin formulations
US5462752A (en) 1994-07-28 1995-10-31 Prp, Inc. Inhibition of platelet binding
AUPM836794A0 (en) 1994-09-23 1994-10-20 University Of New England, The Improved method and composition for the treatment of ulcers
US5643599A (en) * 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
JPH11510046A (ja) 1995-07-21 1999-09-07 ローヌ−プーラン ローラー ファーマシューティカルズ インコーポレイテッド アデノ関連ウイルスリポソーム及び樹状細胞をトランスフェクトして特異性免疫を刺激することにおけるそれらの使用
CN1119145C (zh) 1995-10-11 2003-08-27 埃斯佩里安Luv发展公司 脂质体组合物及其使用方法
AUPN766496A0 (en) 1996-01-22 1996-02-15 University Of New England, The Method and composition for the potentiation of anti-inflammatory drugs
WO1998050527A1 (en) 1997-05-08 1998-11-12 Biomira Inc. Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
AU7685798A (en) 1997-05-29 1998-12-30 Applied Biotechnologies Inc. Compositions and methods for preventing adhesion
SE9702698D0 (sv) 1997-07-14 1997-07-14 Stig Bengmark Compositions for lubricating and separating tissues and biological membranes
EP1054679B1 (en) 1997-12-24 2003-02-12 Britannia Pharmaceuticals Limited Use of surface active agent for the manufacture of a medicament for treatment of disorders of the middle ear
GB9807298D0 (en) 1998-04-03 1998-06-03 Britannia Pharmaceuticals Ltd Medicament
EP0976403A1 (en) 1998-07-30 2000-02-02 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Adjuvant comprising pulmonary surfactant
US6290987B1 (en) * 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6193997B1 (en) 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
HK1044897A1 (zh) 1999-05-14 2002-11-08 Esperion Luv Development Inc. 心绞痛和/或不典型心绞痛的治疗方法及其相关药物组合物和药剂盒
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
CA2319928A1 (en) 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
GB0207653D0 (en) * 2002-04-03 2002-05-15 Lamellar Therapeutics Ltd Methods of using lamellar bodies for therapeutic purposes
EP2823820B1 (en) * 2002-10-29 2018-06-06 Insmed Incorporated Liposomes comprising an aminoglycoside for the treatment of pulmonary infections
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules

Also Published As

Publication number Publication date
NZ546388A (en) 2009-07-31
GB0322448D0 (en) 2003-10-29
US20050070877A1 (en) 2005-03-31
US20130280340A1 (en) 2013-10-24
PT1667693E (pt) 2015-11-12
US20090111773A1 (en) 2009-04-30
US20180153936A1 (en) 2018-06-07
US9173901B2 (en) 2015-11-03
US9750766B2 (en) 2017-09-05
CY1116815T1 (el) 2017-03-15
HUE025129T2 (en) 2016-01-28
ES2543979T3 (es) 2015-08-26
SI1667693T1 (sl) 2015-10-30

Similar Documents

Publication Publication Date Title
IS7977A (is) Samsetningar og aðferð til samsettra meðferðar
IS8305A (is) Bindandi smíðar og aðferðir við notkun þeirra
IS7966A (is) Pyrazól og aðferðir við að búa þau til og notkun þeirra
IS3007B (is) Ónæmisbælandi efnasambönd og efnablöndur
NO20055246D0 (no) Heteroaromatisk pentasyklisk forbindelse og medisinsk anvendelse derav
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1465615T3 (da) Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
DK1539224T3 (da) Antimikrobielt præparat og fremgangsmåde til anvendelse
DK1711207T3 (da) Interferon-alpha-antistoffer og anvendelse heraf
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK1513873T3 (da) Terapeutiske epitoper og anvendelser deraf
IS7726A (is) Pyrazólólpyridín og aðferðir til þess að búa þau til og nota
DK1537096T3 (da) Derivater af dioxan-2-alkylcarbamater, fremstilling og terapeutisk anvendelse heraf
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
IS8529A (is) Rífamísínhliðstæður og notkun þeirra
NO20035562D0 (no) System og fremgangsmåte for forenklet initiering av konferanser
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
DK1667693T3 (da) Præparater og fremgangsmåder til anvendelse af lamellare bodies til terapeutiske formål
NO20033506D0 (no) Parasittdrepende preparater og fremgangsmåter for anvendelse
DK1381382T3 (da) Fremgangsmåder og præparater til behandling af öjensygdomme
DK1589973T4 (da) Formulering og fremgangsmåder til behandling af thrombocytæmi
IS8497A (is) Aðferðir og hvarfefni til að meðhöndla bólgusjúkdóma